Aardvark Therapeutics updates investor presentation on hunger therapies

Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialAn update from Aardvark Therapeutics, Inc. ( (AARD) ) is now available. On January 12, 2026, Aardvark Therapeutics updated and published a new corporate investor presentation outlining its development pipeline and strategic focus on suppressing hunger to treat Prader–Willi syndrome and obesity. The materials highlight late-stage progress of ARD-101 for hyperphagia in Prader–Willi syndrome, including completed Phase 1 and Phase 2 studies that showed reductions in hyperphagia scores with a favorable safety profile, its orphan drug designation, and an ongoing Phase 3 HERO trial with topline data expected in the third quarter of 2026. The update also details ARD-201 programs in obesity for weight maintenance and weight loss, underscoring Aardvark’s ambition to expand treatment options in validated, high-value markets where current therapies are limited, which could strengthen its competitive position if upcoming clinical readouts are positive. The most recent analyst rating on (AARD) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on Aardvark Therapeutics, Inc. stock, see the AARD Stock Forecast page. Spark’s Take on AARD Stock According to Spark, TipRanks’ AI Analyst, AARD is a Neutral. The score is held down primarily by weak financial performance (pre-revenue, widening losses, and significant cash burn), with only partial offset from a constructive technical trend (price above major moving averages with moderate momentum). Valuation provides little support given the negative P/E and no dividend yield. To see Spark’s full report on AARD stock, click here. More about Aardvark Therapeutics, Inc. Aardvark Therapeutics, Inc. is a biopharmaceutical company developing oral therapies that modulate gut-based pathways to suppress hunger, with a focus on treating rare metabolic diseases such as Prader–Willi syndrome and addressing obesity. Its lead investigational products, ARD-101 and ARD-201, target hyperphagia and weight management, positioning the company in markets characterized by severe unmet medical need and significant validated commercial potential. Average Trading Volume: 195,794 Technical Sentiment Signal: Strong Buy Current Market Cap: $315.9M